Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis

PHASE2CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

August 31, 2014

Primary Completion Date

February 17, 2016

Study Completion Date

January 30, 2017

Conditions
Eosinophilic Esophagitis
Interventions
DRUG

RPC4046

DRUG

Placebo

Trial Locations (30)

1011

Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne

4600

Swiss EoE Clinic, Olten

19104

University of Pennsylvania Perelman Center for Advanced Medicine, Philadelphia

20815

Metropolitan Gastroenterology Group Chevy Chase Clinical Research, Chevy Chase

20889

Gastroenterology and Hepatology Service Walter Reed National Military Medical Center, Bethesda

27599

University of North Carolina, Chapel Hill

28801

Asheville Gastroenterology Associates, PA, Asheville

30342

Children's Center for Digestive Healthcare, Atlanta

32256

Borland-Groover Clinic, Jacksonville

32608

University of Florida, Gainesville

37212

Vanderbilt University, Nashville

39232

GI Associates and Endoscopy Center-GI Clinical Research Department, Flowood

44060

Great Lakes Gastroenterology Research, Mentor

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

46202

Indiana University, Indianapolis

49519

West Michigan Clinical Research Center Gastroenterology Associates of Western Michigan, Wyoming

52242

University of Iowa Hospitals and Clinics, Iowa City

55446

Minnesota Gastroenterology, Plymouth

60453

Southwest Gastroenterology, Oak Lawn

60611

Northwestern University-Feinberg School of Medicine, Chicago

80045

University of Colorado School of Medicine, Aurora

83404

Grand Teton Research Group, Idaho Falls

84132

University of Utah Division of Gastroenterology, Salt Lake City

85259

Mayo Clinic - Arizona, Scottsdale

85710

Desert Sun Clinical Research, LLC, Tucson

92056

Alliance Clinical Research, Oceanside

92114

Precision Research Institute, LLC, San Diego

06010

Connecticut Clinical Research Foundation, Bristol

03756

Darthmouth Hitchcock Medical Center, Lebanon

T2N 4Z6

Gastrointestinal Research Group, University of Calgary Health, Calgary

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Celgene

INDUSTRY

NCT02098473 - Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis | Biotech Hunter | Biotech Hunter